Key facts
- Strand Therapeutics’s last known valuation is $571.0M (Aug 2025).
- It has raised $255.6M across 3 recorded rounds; the latest was Later Stage VC (Series B) ($153.0M) in Aug 2025.
- Notable investors include Creative Destruction Lab, MassChallenge, National Institutes of Health, Endless Frontier Labs, ANRI — 30 tracked in total.
- Strand Therapeutics has filed 2 Form Ds with the SEC since 2019, most recently Jul 2021 ($52.1M sold to 13 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 30 names
- ·Watchlist + deal alerts for Strand Therapeutics
Funding rounds
3 roundsAbout Strand Therapeutics
Developer of a medicine infrastructure platform intended to create medicines that respond to disease signals in real-time. The company's platform helps create programmable messenger ribonucleic acid therapies where synthetic biology meets programmable biology for logic-controlled expression, precision delivery, and control over therapeutic outcomes, enabling patients to have improved treatment options for cancer and other life-threatening diseases.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2017
- Employees
- 119
- Website
- strandtx.com/
- Ownership
- Privately Held (backing)
Strand Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Strand Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Strand Therapeutics in its N-PORT filings yet. We sweep new filings monthly.